1. The use of at least one compound containing an amino acid sequence! ! where:! X1 - serine (S), threonine (T) or cysteine (C),! X2 - glutamine (Q), threonine (T) or methionine (M),! X3 - lysine (K) or arginine (R),! X4 - leucine (L), methionine (M),! X5 - tryptophan (W), tyrosine (Y), phenylalanine (F) or isoleucine (I),! X6 - asparagine (N), glutamic acid (E), alanine (A) or cysteine (C),! X7 - cysteine (C),! n and m are independently 0 or 1,! moreover, the compound has the binding ability of an antibody specific for the amyloid beta peptide (Aβ) epitope containing the amino acid sequence HQKLVF and / or HQKLVFFAED. ! for the manufacture of a medicament for the prevention and / or treatment of β-amyloidosis, including Alzheimer's disease. ! 2. The use according to claim 1, wherein the compound contains a peptide having an amino acid sequence selected from the group consisting of SHTRLYF (C), HMRLFFN (C), SHQRLWF (C), HQKMIFA (C), HMRMYFE (C), THQRLWF (C) and HQKMIF (C). ! 3. The use according to claim 1, wherein the compound is a polypeptide containing from 4 to 20 amino acid residues. ! 4. The use according to claim 1, wherein the compound is associated with a pharmaceutically acceptable carrier, preferably fissurella hemocyanin. ! 5. The use according to claim 1, wherein the compound is produced in pharmaceutical form for intravenous, subcutaneous, intradermal or intramuscular administration. ! 6. The use according to claim 1, wherein the compound is produced in pharmaceutical form together with an adjuvant, preferably aluminum hydroxide. ! 7. The use according to claim 1, wherein the compound is contained in the drug in an amount of from 0.1 ng to 10 mg, preferably from 10 ng to 1 mg, in particular from 100 ng to 10 μg. !8.1. Применение по меньшей мере одного соединения, содержащего аминокислотную последовательность ! ! где: ! X1 - серин (S), треонин (Т) или цистеин (С), ! Х2 - глутамин (Q), треонин (Т) или метионин (М), ! Х3 - лизин (К) или аргинин (R
